Loading
Advanced bowel, ovarian or other abdominal cancer can block the bowel. Cramping pain, a swollen tummy, being sick and not passing wind or stools need urgent assessment; a CT scan confirms it. Treatment depends on what you want from care and how well you are: some people have a stent or an operation, many have medicines for sickness and pain, sometimes with a tube to drain the stomach.
MASCC 2022 is the most complete recent guideline: a systematic review to March 2021 producing 25 graded suggestions and recommendations (MASCC levels I to V and grades A to D). MBO is a clinical diagnosis confirmed by contrast CT, which is more valuable than plain X-ray. Decisions are framed by goals of care, prognosis, performance status and where care is given, and a surgical opinion should be considered at diagnosis.
Medicines: a somatostatin analogue (octreotide, lanreotide) is the only recommendation at level I, grade A (to reduce vomiting); MASCC 2021 calls octreotide the drug of choice in non-operable MBO. Haloperidol is suggested, particularly in complete obstruction (IV, B); metoclopramide or domperidone in partial obstruction only, avoided in complete obstruction because of perforation risk (III, B); steroids for short-term benefit (III, B), dexamethasone 4 to 16 mg daily, with discontinuation considered after 3 to 5 days without benefit; hyoscine butylbromide is probably inferior to octreotide for vomiting (III, D); opioids are standard for pain without trial evidence (V, D); osmotic laxatives only in partial obstruction.
Decompression and procedures: nasogastric tube for temporary decompression (V, D); endoscopic or percutaneous venting gastrostomy (IV, B); self-expanding metal stents preferred for single-level large bowel obstruction without perforation (II, B); palliative surgery for multi-level obstruction only in highly selected people (IV, B), given high complication rates. Nutrition: nil by mouth at first, then a slow, symptom-led reintroduction of a low-fibre diet (IV, B); parenteral hydration does not relieve thirst or dry mouth and is not started routinely in the last days of life (III, B); home parenteral nutrition only for a very selected group (IV, D).
Why: CT shows where and why the bowel is blocked, and whether there is a complication such as perforation.
“Contrast computed tomography (CT) is more valuable as it provides diagnostic precision [4].”
Why: The choices range from surgery to comfort care, and the right one depends on what the person wants and how well they are.
“Before offering interventions for MBO management, clinicians should take into consideration the risks associated with the interventions in addition to the patient’s estimated prognosis, performance status, comorbidities, location of care and ease of further assessment and support (e.g., home parenteral nutrition programs may not be universally available).”
Why: A stent, stoma or bypass may be possible and should be considered early, before the person becomes too unwell.
“Obtaining a surgical opinion should be considered at the time of MBO diagnosis.”
Why: Food and tablets cannot pass a complete blockage and make vomiting worse.
“In complete MBO, medication should be administered intravenously or subcutaneously if available.”
Why: It reduces the fluid the gut produces, which is what fills the blocked bowel and causes vomiting.
“Recommendation: Somatostatin analog (octreotide, lanreotide) may reduce vomiting in MBO (levels of evidence: I; grade A).”
MASCC, Supportive Care in Cancer 2022 · Level I; grade A
Why: Metoclopramide pushes the bowel to contract and may risk perforation when it is completely blocked.
“Due to the potential increased risk of bowel perforation, it likely should be avoided in complete MBO.”
MASCC, Supportive Care in Cancer 2022 · Level III; grade B
Why: Steroids may reduce swelling of the bowel wall and help the obstruction settle, but the evidence is limited.
“Suggestion: The use of steroids may help with the acute symptoms of MBO and can be used for short-term benefit (level of evidence: III; grade: B).”
MASCC, Supportive Care in Cancer 2022 · Level III; grade B
Why: Most people with obstruction have pain, and tablets may not be absorbed.
“Suggestion: Opioids are commonly used to treat pain associated with MBO, but there is no evidence to support their use (level of evidence: V; grade D).”
MASCC, Supportive Care in Cancer 2022 · Level V; grade D
Why: Draining the stomach relieves vomiting; a gastrostomy avoids a tube in the nose for weeks.
“Suggestion: Endoscopic or percutaneous gastrostomy tube may be used for gastric decompression in MBO (level of evidence: IV; grade B evidence).”
MASCC, Supportive Care in Cancer 2022 · Level IV; grade B
Why: A stent can reopen the bowel without an operation, with lower early death rates than emergency surgery.
“Self-expanding metallic stents are the preferred alternative for the management of single-level large bowel obstruction when technically feasible and in the absence of colonic perforation (level of evidence: II; grade: B).”
MASCC, Supportive Care in Cancer 2022 · Level II; grade B
Why: Surgery for obstruction in advanced cancer has high complication and re-obstruction rates.
“Patients with advanced cancer that undergo palliative surgery for MBO are at high risk of surgical complications, and less invasive surgical interventions should be considered (level of evidence: IV; grade: B).”
MASCC, Supportive Care in Cancer 2022 · Level IV; grade B
Why: Drip fluids do not ease thirst or a dry mouth at this stage and can cause swelling and breathlessness; mouth care helps more.
“Parenteral hydration should not be initiated routinely in the last days of life (level of evidence: III; grade: B).”
MASCC, Supportive Care in Cancer 2022 · Level III; grade B
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
MASCC 2022 is the most recent graded, multidisciplinary guideline that could be read in full; its strongest recommendation is a somatostatin analogue to reduce vomiting (level I, grade A), consistent with the MASCC 2021 medical update, which calls octreotide the drug of choice in non-operable MBO. Its next strongest is self-expanding metal stents for single-level large bowel obstruction (II, B). Almost everything else (haloperidol, steroids, venting gastrostomy, limits on surgery and on parenteral hydration) rests on level III to V evidence. The North American Delphi consensus (Annals of Surgical Oncology, October 2026) is newer, with 49 statements on assessment, medical, surgical and palliative management, but was read only as an abstract, so where it differs from MASCC is not known.
MASCC, Supportive Care in Cancer 2022 · MASCC, Supportive Care in Cancer 2021 · Annals of Surgical Oncology 2026
Where it differs: Uses hyoscine butylbromide, cheaper and widely available, as the first drug to reduce secretions and vomiting.
Evidence: MASCC 2022 suggests it may be inferior to octreotide for vomiting (III, D); MASCC 2021 found it inferior to octreotide at the doses compared.
MASCC, Supportive Care in Cancer 2022 · MASCC, Supportive Care in Cancer 2021
Where it differs: Feeds intravenously at home, through a central line, for someone with inoperable obstruction who is otherwise well enough to live for months.
Evidence: MASCC 2022: may help quality of life in a very selected group (IV, D); central access preferred (III, B); stop, or do not start, at the end of life (V, D).
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Somatostatin analogue to reduce vomiting | Level I; grade A | MASCC, Supportive Care in Cancer 2022 |
| Octreotide in non-operable MBO “The panel recommends octreotide in non-operable MBO.” | recommendation (MASCC level and category not given in the abstract) | MASCC, Supportive Care in Cancer 2021 |
| Haloperidol, particularly in complete MBO “Suggestion: Haloperidol, a butyrophenone antipsychotic, may be an effective anti-emetic in MBO, particularly for complete MBO (level of evidence: IV; grade: B),” | Level IV; grade B | MASCC, Supportive Care in Cancer 2022 |
| Nasogastric tube for temporary decompression “Suggestion: Nasogastric tube may be used for temporary decompression in acute MBO (level of evidence: V; grade: D).” | Level V; grade D | MASCC, Supportive Care in Cancer 2022 |
| Self-expanding metal stent for single-level large bowel obstruction | Level II; grade B | MASCC, Supportive Care in Cancer 2022 |
| Nil by mouth, then slow symptom-led reintroduction of diet | Level IV; grade B | MASCC, Supportive Care in Cancer 2022 |
Shares CT (computed tomography), Dexamethasone and the tags protocol, acute-oncology, oncological-emergency.
Shares CT (computed tomography), Dexamethasone and the tags protocol, acute-oncology, oncological-emergency.
Shares Dexamethasone and the tags protocol, acute-oncology, oncological-emergency.
Shares Somatostatin analogues (octreotide, lanreotide), Multinational Association of Supportive Care in Cancer, Early integrated palliative care, Dexamethasone and the tags protocol, palliative.
Shares the tags protocol, acute-oncology, oncological-emergency.
Shares the tags protocol, acute-oncology, oncological-emergency.
Shares the tags protocol, acute-oncology, oncological-emergency.
Shares the tags protocol, acute-oncology, oncological-emergency.